The Patent Finder

Deciphera Pharmaceuticals, LLC

77 patents currently held · Updated Nov 18, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

4
Ending by 2030
Oct 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 20, 2026
    The maintenance fee for Methods of Treating Disorders Using CSF1R Inhibitors (US 11,679,110) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Mar 15, 2027
    The maintenance fee for Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities (US 9,133,183) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 4 fees due Apr 10 to 30, 2027 · next Apr 10
  • 3 fees due May 10 to 24, 2027 · next May 10
  • 2 fees due Jun 19 to 26, 2027 · next Jun 19
  • 4 fees due Aug 13 to 27, 2027 · next Aug 13
  • 1 fee due Sep 5, 2027
    The maintenance fee for Compositions of 1-(4-Bromo-5-(1-Ethyl-7-(METHYLAMINO)-2-OXO-1,2-Dihydro-1,6-Naphthyridin-3-YL)-2-Fluoropheyl)-3-Phenylurea (US 11,918,564) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
  • 3 fees due Oct 12 to 30, 2027 · next Oct 12

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,790,756Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,586,565Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,163,756Enzyme modulators and treatments
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,188,113Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
In force (reinstated)
 · From the USPTO record
In force (reinstated)From the USPTO record
US RE48,731Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,133,183Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,181,2232-Aminopyrimidin-6-ONES and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities
In force
 · High confidence
In forceHigh confidence
US 9,193,7191,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,309,224N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,382,228N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 77 patents shown.
Pro members see all 77.
Pro members: see all 77 patents
Also on record, not counted in the 77: 2 patents in force now held by others · 19 lapsed for an unpaid fee · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

19 pending · 7 abandoned · 22 no status recorded

Showing 1 to 10 of 48, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/308,925Amorphous Kinase Inhibitor Formulations and Methods of Use ThereofAug 25, 2025Pending
19/304,158Aug 19, 2025No status recorded
19/194,583Methods of Treating Gastrointestinal Stromal TumorsApr 30, 2025Pending
19/001,282Raf Kinase Inhibitors and Methods of Use ThereofDec 24, 2024Pending
18/985,885Dual Raf and Tubulin Inhibitors and Methods of Use ThereofDec 18, 2024Pending
18/980,426Formulations of a CSF-1R InhibitorDec 13, 2024Pending
18/980,378VPS34 Inhibitors and Methods of Use ThereofDec 13, 2024Pending
18/971,846Formulations of VimseltinibDec 6, 2024Pending
18/971,800Solid Forms of an Ulk InhibitorDec 6, 2024Pending
18/815,054Combination Therapy for the Treatment of MastocytosisAug 26, 2024Pending
10 of 48 applications shown.
Pro members see all 48 published applications.
Pro members: see all 48 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited